The national guide of the Chilean Society of Rheumatology and the American College of Rheumatology recommend that the treatment of a patient with RA begin within the first three months of diagnosis, for which many rheumatologists will select methotrexate as the antirheumatic drug modifier of disease (DMARD) first line in active RA, it is safe and cheap.
However, it is estimated that 15% of patients do not respond with methotrexate and 60% have a partial response. For these patients, other DMARDs with potential to decrease the radiological progression are available Flekosteel: leflunomide, azulfidine, cyclosporin A, injectable gold salts, combinations among them or with biological drugs.
No comments:
Post a Comment